Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma
Phase II trial of Palliative Chemotherapy with TS-1 and Oxaliplatin for Patients with Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
DRUG: SOX
Time to progression (TTP), The time from study enrollment to tumor progression or death, 2 years
overall survival, overall survival, 2 years|response rate, response rate by RECIST 1.1, 2 years|toxicity, toxicity according to NCI-CTCAE v.3.0, 2 years
Phase II trial of Palliative Chemotherapy with TS-1 and Oxaliplatin for Patients with Advanced Hepatocellular Carcinoma